Pamela Valentine

Postal service disruption and the significant hardships these disruptions cause for Canadians and on health charities We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV). Safe Long-Term Care Act with respect to persons affected by MS National Housing Strategy with respect for persons with MS and other chronic conditions and disabilities Measures and funding for the charitable sector generally Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS. Establishment of national strategy for neurological conditions, with respect to persons with MS and other neurological conditions. Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities CIHR as it relates to federal funding & long term investment in health research Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities Canada Health Transfer - health system funding transfer and agreements intended for provinces/territories to support the delivery of healthcare services, including MS care Canada Health Act and regulations, as it relates to long-term and home care Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.